Clearside Biomedical Inc. (CLSD)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
CLSD Chart
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to a loss of $1.5 per share a year ago.
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.1 per share a year ago.
Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know
Clearside Biomedical (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Clearside Biomedical Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TG Tyler Glazier New Millennium Group LLC | 2,952 | $11.72 | - | -$11.72 | -100% |
Clearside Biomedical Inc. (CLSD) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Clearside Biomedical Inc. Profile
| Biotechnology Industry | Healthcare Sector | George Lasezkay CEO | NASDAQ (NMS) Exchange | 185063203 CUSIP |
| US Country | 32 Employees | - Last Dividend | 15 Sep 2025 Last Split | 2 Jun 2016 IPO Date |
Overview
Clearside Biomedical, Inc. is a pioneering biopharmaceutical company founded in 2011, with its headquarters situated in Alpharetta, Georgia. The company is at the forefront of innovating therapeutic delivery specifically to the posterior segment of the eye via the suprachoroidal space. This novel approach is intended to improve the treatment of various eye diseases by targeting the delivery of drugs directly to the affected areas. Clearside Biomedical's commitment to eye health is further evidenced through its collaborative efforts with notable entities such as Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. These collaborations aim to enhance and extend the capabilities and reach of its technologies and offerings in the ophthalmic market.
Products and Services
- XIPERE
- CLS-AX (Axitinib Injectable Suspension)
XIPERE is a cutting-edge therapeutic offering from Clearside Biomedical, comprising a triamcinolone acetonide suprachoroidal injectable suspension. This product is specifically designed for the treatment of uveitis macular edema, a condition characterized by inflammation and swelling in the eye that can lead to severe vision impairment. By delivering the medication via the suprachoroidal space, XIPERE aims to provide targeted relief and treatment outcomes that could potentially surpass those of conventional methods.
CLS-AX represents another frontier in Clearside Biomedical's innovative product lineup, being an axitinib injectable suspension for suprachoroidal injection. Currently in Phase IIb clinical trials, CLS-AX is being developed to treat wet age-related macular degeneration (wet AMD), a leading cause of blindness in older adults. Through its unique delivery system and mechanism of action, CLS-AX holds the promise of significantly improving treatment efficacy and patient outcomes in managing this chronic eye condition.
